Skip to main content
. 2006 Oct;8(10):788–795. doi: 10.1593/neo.06436

Figure 5.

Figure 5

Effect of i.t. injection on the efficacy and toxicity of free and HPMA copolymer-bound doxorubicin. (A) Growth inhibition of subcutaneous AT1 tumors induced by a single i.v. injection of saline (Control; n = 12), a single i.v. injection of 5 mg/kg free doxorubicin (Dox i.v.; n = 9), a single i.t. injection of 5 mg/kg doxorubicin (Dox i.t.; n = 4), a single i.v. injection of 5 mg/kg (doxorubicin-equivalent) poly(HPMA)-GFLG-doxorubicin (PK1 i.v.; n = 7), and a single i.t. injection of 5 mg/kg (doxorubicin-equivalent) poly(HPMA)-GFLG-doxorubicin (PK1 i.t.; n = 4). *P < .05 vs control. #P < .005 vs control. †P < .01 vs Dox i.v. ‡P < .01 vs PK1 i.t. §P < .05 vs DOX i.t. (Mann-Whitney U test). (B) Weight loss induced by the four chemotherapy regimens mentioned above. *P < .05 vs control and PK1 i.v. (Mann-Whitney U test).